Английская Википедия:CovalX

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:More citations needed

Шаблон:Infobox company

CovalX AG is a Zürich, Switzerland-based company that develops innovative analytical solutions for the characterization of biotherapeutics for the life science industry.

Origins

A spin-off of the Swiss Federal Institute of Technology (ETHZ), CovalX was founded by Ryan Wenzel, Alexis Nazabal, and Urs Matter in 2005 as CovalX GmbH and was converted in January 2007 to AG status to allow additional investors into the company.

In 2011, CovalX founded a wholly owned US subsidiary called CovalX Instruments Incorporated located in the Boston area. They began manufacturing and testing of their equipment as well as sales and support for their hardware products.

CovalX developed and patented a technology platform based on mass spectrometry allowing ultra-fast and direct analysis of Protein-protein interactions (PPIs) in solution. After establishing its first laboratory in Zürich, CovalX founded laboratories in Boston (2011) and Bordeaux (2017).

One focus of CovalX was measuring intact protein complexes by MALDI mass spectrometry.[1] They distribute chemical kits, high mass detection hardware and analysis software.

From 2009, CovalX began focusing on analytical service measurements through its growing CRO laboratories in Switzerland and France.

CovalX today is a leader in CRO offering PPI analytical services by mass spectrometry. Taking benefits of its unique technology platform in combination with other methods such as Hydrogen–deuterium exchange by mass-spectrometry (HDX-MS) and Cross-linking by mass-spectrometry (XL-MS), the company helps scientists worldwide in drug development projects.

Awards

In April 2006, CovalX received the CTI Start-up Label from the Swiss Confederation's Commission for Technology and Innovation.[2]

References

Шаблон:Reflist

External links